Amphastar P (AMPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amphastar P (AMPH) has a cash flow conversion efficiency ratio of 0.067x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($51.32 Million) by net assets ($768.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AMPH company net worth for the company's overall valuation and market capitalisation.
Amphastar P - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Amphastar P's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Amphastar P Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amphastar P ranked by their cash flow conversion efficiency. Explore Amphastar P (AMPH) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sichuan Xunyou Network Technology Co Ltd
SHE:300467
|
0.041x |
|
Foxsemicon Integrated Technology Inc
TW:3413
|
-0.012x |
|
Guangdong Senssun Weighing Apparatus Group Ltd
SHE:002870
|
0.049x |
|
Chengdu RML Technology Co. Ltd.
SHE:301050
|
N/A |
|
Amerant Bancorp Inc.
NYSE:AMTB
|
0.024x |
|
Vertex
NASDAQ:VERX
|
0.140x |
|
Shunfa Hengye Corp
SHE:000631
|
0.000x |
|
Plymouth Industrial REIT Inc
NYSE:PLYM
|
0.036x |
Annual Cash Flow Conversion Efficiency for Amphastar P (2012–2025)
The table below shows the annual cash flow conversion efficiency of Amphastar P from 2012 to 2025. View AMPH stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $788.80 Million | $156.12 Million | 0.198x | -32.08% |
| 2024-12-31 | $732.30 Million | $213.39 Million | 0.291x | +1.54% |
| 2023-12-31 | $639.42 Million | $183.50 Million | 0.287x | +70.12% |
| 2022-12-31 | $528.66 Million | $89.18 Million | 0.169x | -23.30% |
| 2021-12-31 | $445.52 Million | $97.99 Million | 0.220x | +72.35% |
| 2020-12-31 | $448.72 Million | $57.27 Million | 0.128x | +30.65% |
| 2019-12-31 | $427.53 Million | $41.76 Million | 0.098x | -6.81% |
| 2018-12-31 | $364.36 Million | $38.19 Million | 0.105x | -9.82% |
| 2017-12-31 | $337.33 Million | $39.21 Million | 0.116x | -0.75% |
| 2016-12-31 | $329.25 Million | $38.56 Million | 0.117x | +224.01% |
| 2015-12-31 | $295.51 Million | $10.68 Million | 0.036x | -51.61% |
| 2014-12-31 | $281.86 Million | $21.05 Million | 0.075x | -39.48% |
| 2013-12-31 | $251.54 Million | $31.04 Million | 0.123x | +1845.92% |
| 2012-12-31 | $233.44 Million | $-1.65 Million | -0.007x | -- |
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more